2 results match your criteria: "Hospitals of the University of the Saarland[Affiliation]"
Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.
Thromb Res
September 2014
Institute of Medical Biostatistics, Epidemiology and Informatics, Division Medical Biometry, University Medical Center, Johannes Gutenberg University, Mainz, Germany; Formerly of: Institute of Medical Biostatistics, Epidemiology and Informatics, University of the Saarland, Homburg/Saar, Germany.
Introduction: Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder.
View Article and Find Full Text PDFHealth-related quality of life in hereditary hemorrhagic telangiectasia.
Otolaryngol Head Neck Surg
May 2007
Department of Otorhinolaryngology, Hospitals of the University of the Saarland, Homburg/Saar, Germany.
Objective: To assess and differentiate the health-related quality of life (HR-QoL) in patients with hereditary hemorrhagic telangiectasia (HHT).
Study Design And Setting: A prospective, open, cross-sectional questionnaire-based study (including the Short Form-36 Health Survey [SF-36]) performed by a tertiary care center.
Results: A total of 77 patients (36 females) were included.